| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008864 Treatment of diseases involving cyst formation |
| 01/09/2003 | US20030008863 Novel tricyclic diazepines tocolytic oxytocin receptor antagonists |
| 01/09/2003 | US20030008862 Function as sulfatase and/or blocking estrogen receptors; prophylaxis and therapy |
| 01/09/2003 | US20030008860 Treatment of congestive heart failure |
| 01/09/2003 | US20030008859 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 01/09/2003 | US20030008858 Therapeutic treatment for sexual dysfunction |
| 01/09/2003 | US20030008856 Treatment of septic shock |
| 01/09/2003 | US20030008854 Use of NF-kappabeta inhibitors to treat dry eye disorders |
| 01/09/2003 | US20030008853 Administering 22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3 alpha ,4 beta ,5 alpha , 6 alpha ,7 beta ,14 beta ,22S)-stigmastan-15-one and carrier for wetting eye |
| 01/09/2003 | US20030008852 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 01/09/2003 | US20030008851 Acne treatment including dual-package system |
| 01/09/2003 | US20030008849 For therapy of diseases mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss |
| 01/09/2003 | US20030008847 Treatment of diabetes and related pathologies |
| 01/09/2003 | US20030008846 Use of dopamine receptor antagonists in palliative tumor therapy |
| 01/09/2003 | US20030008845 Conjugated nonadecadienoic acid compositions |
| 01/09/2003 | US20030008844 Administering formulatin comprising iduronylglycosaminoglycan sulfate and dermatan sulfate or their salts, solvates, hydrates or clathartes for therapy and prophylaxis of inflammatory bowel disease |
| 01/09/2003 | US20030008843 Bulking agents as satiety agents |
| 01/09/2003 | US20030008842 Formulations of adenosine a1 agonists |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008838 Method of increasing endogenous leptin production |
| 01/09/2003 | US20030008835 Bioavailability of drug substance, are convenient to administer, and are stable |
| 01/09/2003 | US20030008834 Compsoitions and methods for treating epithelia and retinal tissue diseases |
| 01/09/2003 | US20030008833 Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs |
| 01/09/2003 | US20030008832 Method of inhibiting neoplastic cells with benzimidazole derivatives |
| 01/09/2003 | US20030008824 Stimulation of vascularization with VEGF-B |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008817 Cross-link reversing agent |
| 01/09/2003 | US20030008810 Nutritional intervention composition for enhancing and extending satiety |
| 01/09/2003 | US20030008809 Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases |
| 01/09/2003 | US20030008807 Novel signaling pathway for the production of inflammatory pain and neuropathy |
| 01/09/2003 | US20030008806 Inhibitors of phosphodiesterases (PDEs) such as papaverine for treatment of drug dependence and psychological disorders |
| 01/09/2003 | US20030008805 Comprises beta-adrenergic receptor agonist such as clenbuterol; improves tear secretion; reduced side effects on the heart |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008391 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008376 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/09/2003 | US20030008369 Genetic and epigenetic manipulation of ABC transporters and ecto-phosphatases |
| 01/09/2003 | US20030008300 Amplification of nitroso compouds in erythrocytes; obtain mammal, inject with therapeutic agent, monitor concentration levels of preferential nitroso compounds |
| 01/09/2003 | US20030008295 Nucleic acid sensor molecules |
| 01/09/2003 | US20030008284 Polynucleotides related to colon cancer |
| 01/09/2003 | US20030008279 Cells for use in the diagnosis and treatment of viral diseases |
| 01/09/2003 | US20030008274 Nucleotide sequences coding polypeptide for use in the treatment of and prevention of viral diseases |
| 01/09/2003 | US20030008273 Methods for increasing the survival of neuronal cells |
| 01/09/2003 | US20030008048 Lipid soluble soft gel cap; hard water soluble capsule shell |
| 01/09/2003 | US20030008025 Composition for inhibiting increase of blood sugar level or lowering blood sugar level |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008020 Sexual disorders; vasodilation |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030008015 Controlled drug delivery; anticancer agent |
| 01/09/2003 | US20030008012 Bactericide in solid form |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030008005 Sublingual administration of dihydroergotamine for the treatment of migraine |
| 01/09/2003 | US20030008004 Gabapentin; spray coating with binder solution; compression |
| 01/09/2003 | US20030008003 Compositions for enhanced absorption of NSAIDs |
| 01/09/2003 | US20030008002 Containing titanium dioxide platelets |
| 01/09/2003 | US20030007998 Unsaturated lipid-enriched feedstock for ruminants |
| 01/09/2003 | US20030007994 Releasing estrogen and cyclodextrin |
| 01/09/2003 | US20030007992 Zero-order prolonged release coaxial implants |
| 01/09/2003 | US20030007989 Cyclic applying of pesticides |
| 01/09/2003 | US20030007988 Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (PNP) |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007966 Adult respiratory distress syndrome |
| 01/09/2003 | US20030007962 Pharmaceutical composition containing mosapride and pancreatin |
| 01/09/2003 | US20030007960 Oral administering of protein as protease inhibitor; rheumatic diseases |
| 01/09/2003 | US20030007959 Oral methods of treatment |
| 01/09/2003 | US20030007958 Mixture of silica, flow control agent and carrier; cyclooxygenase inhibitor, antiinflammatory agents |
| 01/09/2003 | US20030007951 Applying anionic polymer; antiinflammatory agents, antiulcer agents |
| 01/09/2003 | US20030007949 Adhesive treatment for tinea corporis |
| 01/09/2003 | US20030007948 Applying polymerizable monomer and fungicide; applying to skins |
| 01/09/2003 | US20030007947 Applying polymerizable monomer and fungicide; applying to mouth |
| 01/09/2003 | US20030007946 Applying polymerizable monomer and fungicide; applying to skins |
| 01/09/2003 | US20030007941 Method of treating hair loss using thyromimetic compounds |
| 01/09/2003 | US20030007934 Delivery of stimulants through an inhalation route |
| 01/09/2003 | US20030007933 Delivery of muscle relaxants through an inhalation route |
| 01/09/2003 | US20030007932 Drug delivery; overcoated solid dried active solid |
| 01/09/2003 | US20030007931 Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS) |
| 01/09/2003 | US20030007929 Topical steroid spray |
| 01/09/2003 | US20030005925 Delivery of rizatriptan or zolmitriptan through an inhalation route |
| 01/09/2003 | US20030005924 Delivery of beta-blockers through an inhalation route |
| 01/09/2003 | CA2501846A1 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2489681A1 Aryl boronic acids for treating obesity |
| 01/09/2003 | CA2487857A1 Aryl boronate functionalized polymers for treating obesity |
| 01/09/2003 | CA2455654A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | CA2452393A1 Hydrophobic dopamine agonists administered to the dermis |
| 01/09/2003 | CA2452390A1 Use of tyrosine kinase inhibitors for treating bone loss |
| 01/09/2003 | CA2452371A1 Use of tyrosine kinase inhibitors for treating allergic diseases |
| 01/09/2003 | CA2452368A1 New potent, selective and non toxic c-kit inhibitors |
| 01/09/2003 | CA2452361A1 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 01/09/2003 | CA2452321A1 Enhanced pharmacokinetic profile of hydrophobic substances |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452192A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 01/09/2003 | CA2452171A1 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | CA2452169A1 Use of tyrosine kinase inhibitors for treating inflammatory diseases |
| 01/09/2003 | CA2452167A1 Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452039A1 Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| 01/09/2003 | CA2452030A1 Sustained release pharmaceutical composition |
| 01/09/2003 | CA2451975A1 Tolterodine metabolites |